Jazz Pharmaceuticals
JAZZ
500 hedge funds and large institutions have $7.03B invested in Jazz Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 80 funds opening new positions, 164 increasing their positions, 179 reducing their positions, and 58 closing their positions.
38% more first-time investments, than exits
New positions opened: 80 | Existing positions closed: 58
22% more call options, than puts
Call options by funds: $41M | Put options by funds: $33.5M
3% more funds holding
Funds holding: 484 → 500 (+16)
1.26% more ownership
Funds ownership: 89.52% → 90.78% (+1.3%)
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
4% less capital invested
Capital invested by funds: $7.33B → $7.03B (-$298M)
8% less repeat investments, than reductions
Existing positions increased: 164 | Existing positions reduced: 179
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$84.2M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
+$80.6M |
| 3 |
AC
Armistice Capital
New York
|
+$42.3M |
| 4 |
Pacer Advisors
Malvern,
Pennsylvania
|
+$28.1M |
| 5 |
Jane Street
New York
|
+$23.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$136M |
| 2 |
SC
Samlyn Capital
New York
|
-$91.9M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$48.5M |
| 4 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$38.5M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$38.5M |
JAZZ Hedge Fund Activity: Q4 2023 in Review
500 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Jazz Pharmaceuticals (JAZZ) for Q4 2023, worth a combined $7.03B — down 4.1% from $7.33B a quarter earlier.
Buyers outnumbered sellers: 80 funds opened new JAZZ positions and 58 closed out — a net gain of 22 holders — while 164 added to existing stakes and 179 trimmed.
The largest buyer was Camber Capital Management, opening a new position worth an estimated $84.2M. The largest seller was Deep Track Capital, cutting an estimated $136M.
- 500 institutional investors held Jazz Pharmaceuticals (JAZZ) as of Q4 2023, up from 484 in Q3 2023.
- Funds reported $7.03B of Jazz Pharmaceuticals stock for Q4 2023, down 4.1% quarter-over-quarter.
- 80 funds opened new Jazz Pharmaceuticals positions in Q4 2023 and 58 closed out, a net change of +22 holders.
- The largest Jazz Pharmaceuticals buyer in Q4 2023 was Camber Capital Management, an estimated $84.2M added.
- The largest Jazz Pharmaceuticals seller in Q4 2023 was Deep Track Capital, an estimated $136M sold.
Based on aggregated 13F filings for Q4 2023.